NASDAQ:FBIO - Fortress Biotech Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.91 -0.12 (-5.91 %) (As of 08/20/2018 06:36 AM ET)Previous Close$2.03Today's Range$1.91 - $2.015852-Week Range$1.41 - $5.54Volume88,973 shsAverage Volume157,657 shsMarket Capitalization$110.57 millionP/E Ratio-1.19Dividend YieldN/ABeta0.1 Company ProfileAnalyst RatingsChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Fortress Biotech, Inc. develops and commercializes pharmaceutical and biotechnology products. The company develops CNDO-109, a lysate that treats cancer-related and other conditions; tramadol HCl for managing postoperative pain; CAEL-101 for the treatment of amyloid light chain amyloidosis; and CEVA101 for severe traumatic brain injury in children and adults in the United States. It also develops CK-301 for treating patients with non-small cell lung cancer (NSCLC); CK-101 for the treatment of patients with epidermal growth factor receptor mutation-positive NSCLC; and antibodies that target glucocorticoid-induced TNFR-related protein and carbonic anhydrase IX, as well as anti-cancer agents that inhibit bromodomain and extra-terminal proteins, and poly polymerase. In addition, the company develops CUTX-101 for treating Menkes disease; preclinical adeno-associated virus gene therapies for treating mucopolysaccharidosis type 1, dysferlinopathies, and corneal transplant rejection; Triplex, which is in Phase II clinical study for preventing and treating cytomegalovirus (CMV); and Pentamer, a vaccine drug candidate for preventing CMV. Further, it offers Targadox, a tablet for severe acne; Luxamend wound cream; Ceracade for treating dry skin conditions; Triderm for treating eczema, dermatitis, allergies, and rash; and chimeric antigen receptor and engineered T cell therapies across various cancers. Additionally, it provides retail brokerage and wealth management services to high net worth individual and institutional clients; investment banking, merger and acquisition, and advisory services to micro, small, and mid-cap high growth companies; trades in securities; liquidity services; and tax preparation, fixed insurance sales, and licensed mortgage brokerage services. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was founded in 2006 and is based in New York, New York. Receive FBIO News and Ratings via Email Sign-up to receive the latest news and ratings for FBIO and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical SymbolNASDAQ:FBIO CUSIP21976U10 Webwww.fortressbiotech.com Phone781-652-4500 Debt Debt-to-Equity Ratio0.76 Current Ratio2.76 Quick Ratio2.76 Price-To-Earnings Trailing P/E Ratio-1.19 Forward P/E Ratio-0.75 P/E GrowthN/A Sales & Book Value Annual Sales$187.58 million Price / Sales0.55 Cash FlowN/A Price / CashN/A Book Value$2.38 per share Price / Book0.80 Profitability EPS (Most Recent Fiscal Year)($1.61) Net Income$-66,870,000.00 Net Margins-47.97% Return on Equity-71.96% Return on Assets-32.29% Miscellaneous Employees68 Outstanding Shares54,340,000Market Cap$110.57 million Fortress Biotech (NASDAQ:FBIO) Frequently Asked Questions What is Fortress Biotech's stock symbol? Fortress Biotech trades on the NASDAQ under the ticker symbol "FBIO." How were Fortress Biotech's earnings last quarter? Fortress Biotech (NASDAQ:FBIO) issued its earnings results on Friday, August, 10th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.59) by $0.09. The biopharmaceutical company had revenue of $63.83 million for the quarter, compared to analysts' expectations of $48.93 million. Fortress Biotech had a negative return on equity of 71.96% and a negative net margin of 47.97%. View Fortress Biotech's Earnings History. When is Fortress Biotech's next earnings date? Fortress Biotech is scheduled to release their next quarterly earnings announcement on Thursday, November, 8th 2018. View Earnings Estimates for Fortress Biotech. What price target have analysts set for FBIO? 3 equities research analysts have issued 1 year target prices for Fortress Biotech's shares. Their predictions range from $10.00 to $11.00. On average, they expect Fortress Biotech's share price to reach $10.6667 in the next year. This suggests a possible upside of 458.5% from the stock's current price. View Analyst Price Targets for Fortress Biotech. What is the consensus analysts' recommendation for Fortress Biotech? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fortress Biotech in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Fortress Biotech. Who are some of Fortress Biotech's key competitors? Some companies that are related to Fortress Biotech include Synergy Pharmaceuticals (SGYP), Magenta Therapeutics (MGTA), Merus (MRUS), ZEALAND PHARMA/S (ZEAL), ZIOPHARM Oncology (ZIOP), Dermira (DERM), Evelo Biosciences (EVLO), Syros Pharmaceuticals (SYRS), American Brivision (Holding) (ABVC), Xeris Pharmaceuticals (XERS), GTX (GTXI), Vital Therapies (VTL), MediciNova (MNOV), Keryx Biopharmaceuticals (KERX) and Sinovac Biotech (SVA). Who are Fortress Biotech's key executives? Fortress Biotech's management team includes the folowing people: Dr. Lindsay Allan Rosenwald, Exec. Chairman, Pres & CEO (Age 63)Dr. Eric K. Rowinsky, Co-Vice Chairman & Consultant (Age 61)Mr. Michael S. Weiss, Exec. Vice Chairman of Strategic Devel. (Age 52)Ms. Robyn M. Hunter, CFO, Treasurer & Corp. Sec. (Age 56)Mr. George C. Avgerinos, Sr. VP of Biologics Operations (Age 64) Has Fortress Biotech been receiving favorable news coverage? Media coverage about FBIO stock has trended somewhat negative recently, according to Accern Sentiment Analysis. The research group identifies positive and negative press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Fortress Biotech earned a coverage optimism score of 0.00 on Accern's scale. They also assigned media headlines about the biopharmaceutical company an impact score of 47.27 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future. View Recent Headlines for Fortress Biotech. Who are Fortress Biotech's major shareholders? Fortress Biotech's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (3.60%), Strs Ohio (0.38%), Acadian Asset Management LLC (0.29%) and Macquarie Group Ltd. (0.19%). Company insiders that own Fortress Biotech stock include George Avgerinos and Lindsay A Md Rosenwald. View Institutional Ownership Trends for Fortress Biotech. Which major investors are buying Fortress Biotech stock? FBIO stock was bought by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, BlackRock Inc., Strs Ohio and Macquarie Group Ltd.. View Insider Buying and Selling for Fortress Biotech. How do I buy shares of Fortress Biotech? Shares of FBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Fortress Biotech's stock price today? One share of FBIO stock can currently be purchased for approximately $1.91. How big of a company is Fortress Biotech? Fortress Biotech has a market capitalization of $110.57 million and generates $187.58 million in revenue each year. The biopharmaceutical company earns $-66,870,000.00 in net income (profit) each year or ($1.61) on an earnings per share basis. Fortress Biotech employs 68 workers across the globe. How can I contact Fortress Biotech? Fortress Biotech's mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The biopharmaceutical company can be reached via phone at 781-652-4500 or via email at [email protected] MarketBeat Community Rating for Fortress Biotech (NASDAQ FBIO)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 194 (Vote Outperform)Underperform Votes: 165 (Vote Underperform)Total Votes: 359MarketBeat's community ratings are surveys of what our community members think about Fortress Biotech and other stocks. Vote "Outperform" if you believe FBIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FBIO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 8/20/2018 by MarketBeat.com StaffFeatured Article: How do investors use RSI to grade stocks?